September 20, 2016 01:05 ET | Source: TiGenix LEUVEN, Belgium, Sept. 20, 2016 (GLOBE NEWSWIRE) — TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, today reported its business and financial highlights for the first half of 2016. Below are […]